# Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

> **NCT02178475** · — · COMPLETED · sponsor: **Amgen** · enrollment: 943 (actual)

## Conditions studied

- Chemotherapy-induced Febrile Neutropenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02178475
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-18
- **Primary completion:** 2016-10-28
- **Final completion:** 2016-10-28
- **Target enrollment:** 943 (ACTUAL)
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178475, "Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02178475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*